U.S. product exclusion extensions, medical-care products imported from China (COVID-19)

The Office of the U.S. Trade Representative (USTR) today released for publication in the Federal Register a notice concerning the Section 301 investigation of China’s acts, policies, and practices related to technology transfer, intellectual property, and innovation.

Prior USTR notices excluded from additional customs duties certain medical-care products that were intended to address the coronavirus (COVID-19) disease. 

• The USTR in March 2021 extended certain product exclusions—that is, removed Section 301 customs duties from medical-care products that address COVID-19—through September 30, 2021. Read TradeNewsFlash
• The USTR in August 2021 requested comments on whether to extend the exclusions for up to six months. Read TradeNewsFlash

Today’s notice [PDF 204 KB] announces the USTR’s determination to adopt an interim extension of these exclusions for 45 days in order to provide time to review the public comments. The extensions announced in the notice will extend the product exclusions through November 14, 2021.

For more information on this topic or to learn more about KPMG’s Trade & Customs Services, contact: